Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
The crypto market continues to rise, with BTC approaching $67,000, while only the DeFi sector is declining

The crypto market continues to rise, with BTC approaching $67,000, while only the DeFi sector is declining

Odaily星球日报Odaily星球日报2026/07/22 02:27
Show original

According to Odaily, on July 22, based on SoSoValue data, the crypto market sectors maintained an upward trend. Bitcoin (BTC) rose by 1.83%, approaching $67,000 at one point; Ethereum (ETH) gained 1.38%, surpassing $1,900. At the same time, SocialFi and RWA sectors performed notably well, rising 6.15% and 5.85% respectively over 24 hours. Within the SocialFi sector, Gram (GRAM) increased by 6.89%. In the RWA sector, Ondo Finance (ONDO) jumped 11.68%, Centrifuge (CFG) climbed 6.25%, while Plume (PLUME) and RE gained 8.20% and 12.04% respectively.

In other sectors, the PayFi sector increased by 2.24% in 24 hours, with Monero (XMR) up 6.24%. The Meme sector rose by 0.80%, with SPX6900 (SPX) up 4.94%. The Layer2 sector gained 0.62%, with Optimism (OP) up 5.02%. Layer1 sector increased by 0.33%, with Hedera (HBAR) up 4.87%. In the CeFi sector, Bitget Token (BGB) rose by 2.53%.

Additionally, the DeFi sector fell by 2.54%, but ZeroLend (ZERO) defied the trend with an increase of 50.73%.

The crypto sector indices reflecting historical market trends show that the ssiSocialFi, ssiRWA, and ssiPayFi indices rose by 6.22%, 5.44%, and 2.39% respectively.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma